Published in Anticancer Agents Med Chem on May 01, 2006
Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal (2008) 1.28
Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas (2010) 1.11
Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol Immunol (2008) 1.08
Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol (2011) 0.93
Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas (2013) 0.91
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer (2011) 0.90
COX-2 in cancer: Gordian knot or Achilles heel? Front Pharmacol (2013) 0.89
Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin Ther Targets (2009) 0.88
Exploiting the tumor microenvironment for theranostic imaging. NMR Biomed (2011) 0.85
Chemoprevention of lung cancer. Proc Am Thorac Soc (2009) 0.81
The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. Carcinogenesis (2013) 0.81
Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response. Cancer Immunol Immunother (2009) 0.80
Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells. NMR Biomed (2011) 0.79
Chemoprevention of lung cancer: prospects and disappointments in human clinical trials. Cancers (Basel) (2013) 0.78
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. Oncologist (2015) 0.78
Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through AKT-Dependent Downregulation of Survivin. Cancer Res Treat (2014) 0.77
Timosaponin AIII Suppresses Hepatocyte Growth Factor-Induced Invasive Activity through Sustained ERK Activation in Breast Cancer MDA-MB-231 Cells. Evid Based Complement Alternat Med (2013) 0.77
Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila) (2016) 0.76
DNA Damage in Healthy Individuals and Respiratory Patients after Treating Whole Blood In vitro with the Bulk and Nano Forms of NSAIDs. Front Mol Biosci (2016) 0.75
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget (2017) 0.75
Lung cancer chemoprevention. Proc Am Thorac Soc (2012) 0.75
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget (2017) 0.75
Nonsteroidal Anti-inflammatory Drug Interaction with Prostacyclin Synthase Protects from Miscarriage. Sci Rep (2017) 0.75
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol (2005) 2.48
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res (2006) 2.47
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res (2005) 2.32
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst (2009) 1.75
Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res (2005) 1.74
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012) 1.70
Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med (2009) 1.60
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
Aromatase inhibitors in human lung cancer therapy. Cancer Res (2005) 1.55
Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res (2010) 1.44
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res (2009) 1.43
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res (2013) 1.41
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res (2005) 1.37
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33
Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc (2008) 1.31
IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest (2002) 1.29
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol (2008) 1.28
COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J (2003) 1.24
Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat (2004) 1.22
The role of miRNA in inflammation and autoimmunity. Autoimmun Rev (2013) 1.22
CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci (2004) 1.18
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res (2006) 1.18
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res (2004) 1.17
Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.17
Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther (2007) 1.14
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol (2007) 1.13
IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol (2009) 1.12
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 1.12
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol (2006) 1.12
SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer (2003) 1.11
Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res (2004) 1.10
Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res (2004) 1.09
Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging (2008) 1.08
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res (2013) 1.07
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. J Natl Compr Canc Netw (2013) 1.07
Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope (2010) 1.07
COX-2 inhibition and lung cancer. Semin Oncol (2004) 1.06
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol (2014) 1.05
Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res (2006) 1.05
Evolving concepts in lung carcinogenesis. Semin Respir Crit Care Med (2011) 1.03
EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol (2007) 1.02
Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One (2011) 1.01
Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res (2004) 1.01
Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer (2011) 1.00
MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 1.00
The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One (2009) 1.00
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther (2013) 0.99
Chemokines: can effector cells be redirected to the site of the tumor? Cancer J (2010) 0.98
Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol (2006) 0.98
Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol (2004) 0.98
EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol (2003) 0.97
CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer (2009) 0.97
IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol (2003) 0.96
Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila) (2014) 0.96
Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol (2008) 0.95
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer (2005) 0.95
Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer (2003) 0.94
PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One (2012) 0.94
Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One (2012) 0.93
PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol (2005) 0.93